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Thoracic EndoVascular Stent Graft Repair for Aortic Aneurysm 
Joung  Taek  Kim,  M.D.*,  Yong  Han  Yoon,  M.D.*,  Hyun  Kyung  Lim,  M.D.**, 
Ki  Hwan  Yang,  M.D.**,  Wan  Ki  Baek,  M.D.*,  Kwang  Ho  Kim,  M.D.*
Background:  The number of cases employing thoracic endovascular aortic repair (TEVAR) has been increasing due 
to lower morbidity and mortality compared to open repair technique. The aim of this study is to evaluate the out-
come of TEVAR for thoracic aortic diseases. Materials and Methods: Sixteen patients underwent TEVAR from 
October 2003 to April 2010. Mean age at operation was 59 years (20∼78 years), and 11 were male. Indications 
for TEVAR were large aortic diameter (＞5.5 cm) upon presentation in 6 patients, increasing aortic diameter during 
the follow-up period in 4, traumatic aortic rupture in 3, persistent chest pain in 2, and ruptured aortic aneurysm in 
one. The mean diameter, length and the number of the stents were 33 mm (26∼40 mm), 12 cm (9.5∼16.0 cm), 
and 1.25 (1∼2), respectively. Aortography employing Multi-detector computerized tomography (MDCT) technique was 
performed at one week, and patients were followed up in the out-patient department at one month, 6 months, and 
one year postoperatively. Results: Primary technical success showing complete exclusion of the aneurysm was ach-
ieved in 15 patients. One patient showed a small endo-leak (type 1). Four patients developed perioperative stroke: 
Three recovered without sequelae, and one showed mild right-side weakness. There was no operative mortality. 
Diameter of the thoracic aorta covered by stent graft changed within 10% range in 12 patients, decreased by 
more than 10% in 3, and increased by more than 10% in one during mean follow-up duration of 18 months (1∼
73 months). There was no recurrence-related death during this period. Conclusion: Intermediate-term outcome after 
TEVAR was encouraging. Indications for TEVAR could be extended for other thoracic aortic diseases. 




After  stent  graft  implantation  became  a  standard  procedure 
for infra-renal abdominal aortic aneurysm, the number of cas-
es  of  thoracic  endovascular  aortic  repair  (TEVAR)  in  Korea 
has been rapidly increasing [1-3], substantiated by the reports 
from Korean Health  Insurance  Review  & Assessment Service 
(Fig.  1).  Stent  graft,  which  consists  of  prosthetic  material, 
such  as  Dacron  or  Gore-Tex  patches,  embedded  in  the  cylin-
drical  metallic  frame,  is  devised  to  separate  aortic  aneurysm 
from true aortic lumen, and thus interrupt the blood flow into 
the  aneurysm. Because  TEVAR  eliminates the  basic  elements 
of  surgical  intervention  (i.e.  thoracotomy,  left  heart  bypass, 
aortic  cross-clamping  and  deep  hypothermic  circulatory  ar-Thoracic EndoVascular Stent Graft Repair for Aortic Aneurysm
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Table 1. Aortic diseases of the patients treated with TEVAR* (N= 
16)
No.  of  patients
Descending  thoracic  aortic  aneurysm 4
Chronic  aortic  dissection 4 
  T y p e  A  a o r t i c  d i s s e c t i o n 2
    Type  B  aortic  dissection 2 
Traumatic  aortic  rupture  3
Aortic  arch  aneurysm 2 
Acute  type  B  aortic  dissection  2
Descending  thoracic  aortic  pseudo-aneurysm 1 
*=Thoracic  endovascular  aortic  repair.
Fig. 1. Number of patients treated with TEVAR in Korea*. *=Data 
was provided by Korean Health Insurance review & assessment 
service. TEVAR=Thoracic endovascular aortic repair.
Fig. 2. Three-Dimensional reconstruction of MDCT image after hy-
brid TEVAR. The arrows indicate de-branched innominate artery 
and left common carotid artery. MDCT=Multi-detector computed to-
mography; TEVAR=Thoracic endovascular aortic repair.
Table 2. Indications for TEVAR*
No.  of  patients
Aortic  diameter  ≥5.5  cm 6
False  lumen  enlargement 4 
Traumatic  rupture  3
Persistent  back/chest  pain 2 
Aortic  aneurysm  rupture 1
*=Thoracic  endovascular  aortic  repair.
rest),  this  new  therapeutic  modality  is  believed  to  lower  the 
risks  of morbidity  and mortality in descending thoracic aortic 
aneurysm,  traumatic  aortic  rupture  and  type  B  aortic  dis-
section [2]. Furterhmore, when the application of TEVAR for 
aortic  arch  aneurysm  is  difficult  because  proximal  landing 
z o n e  ( P L Z )  f o r  s t e n t  g r a f t  o v e r r i d e s  t h e  o r i g i n  o f  t h e  a r c h  
vessels,  hybrid  procedure  (i.e.  surgical  debranching  of  the 
arch  vessels  plus  TEVAR)  has  been  recently  developed  [3]. 
In  this  study,  we  sought  to  determine  the  intermediate-term 
results  of  TEVAR  for  thoracic  aortic  aneurysm.
MATERIALS AND METHODS
    The  study  cohort  comprises  16  patients  who  underwent 
TEVAR  between  October  2003  and  April  2010.  Median  age 
at TEVAR was 59 years (20∼78 years), and 11 were males. 
Types  of  aortic  lesion  were  descending  thoracic  aortic  aneur-
ysm in 4, chronic aortic dissection in 4, traumatic aortic rup-
tu re in 3 , aor tic ar ch an eur ysm in 2 , acute type B ao rtic dis-
section  in  2,  and  descending  thoracic  aorta  pseudoaneurysm 
in  1  (Table  1).  Associated  morbidities  were  systemic  hyper-
tension  in  7,  multiple  trauma  in  3 ,  a  h i s t o r y  o f  a s c e n d i n g  
aortic  replacement  for  previous  type  A  aortic  dissection  in  2, 
diabetes mellitus in 2, and aortic rupture in 1. Indications for 
TAVAR were dilated aortic diameter equal to or greater than 
5.5  cm  (n=6),  increase  in  aortic  size  during  the  follow-up 
(n=4),  traumatic  aortic  rupture  (n=3),  persistent  chest  pain 
(n=2),  and  ruptured  aortic  aneurysm  (n=1)  (Table  2).  Mean 
diameter  of  the  stent  used f o r  T E V A R  w a s  3 3  m m  ( 2 6 ∼40 
mm), and mean number of the stent per a patient was 1.25 (1Joung Taek Kim, et al
− 150  −
Fig. 3. Follow-up MDCT aortog-
raphy shows the increased aortic di-
ameter after TEVAR (B) compared 
with preoperative image (A).
∼2).  All  patients  underwent  multi-detector  computed  tomog-
raphy (MDCT) for the assessment of thoraco-abdominal aorta, 
and  sufficient  PLZ  was  defined  by  aortic  diameter  (≤40 
mm) and length (≥2 cm) on MDCT. If the length of normal 
aorta  is  insufficient  for  PLZ,  TEVAR  was  preceded  by  de-
branching  surgery  of  the  arch  vessels  (Fig.  2).  With  respect 
to  the  intra-operative  safety  measures,  cerebrospinal  fluid 
drainage was done in a patient whose distal landing zone was 
to  be  below  the  level  of  8
th  thoracic  vertebra,  and  intra-
operative  electroencephalography  (EEG)  monitoring  was  done 
for  patients  with  debranching  surgery.  Under  general  or  epi-
dural  anesthesia,  right  femoral  a r t e r y  w a s  e x p o s e d  f o r  t h e  
catheter sheath insertion, and left  femoral  artery  or  left  radial 
artery  was  punctured  to  introduce  a  reference  catheter,  5 
French  in  size,  which  was  used  to  determine  the  exact  loca-
t i o n  o f  D L Z .  A f t e r  5 , 0 0 0  I U  o f  h e p a r i n  w a s  a d m i n i s t e r e d ,  a  
s t e n t  g r a f t  ( S e a l  f l e x ,  S  &  G  C o ,  K o r e a )  w a s  i n t r o d u c e d  
through  the  sheath  in  the  right  femoral  artery  up  to  the  level 
of  pre-determined  PLZ  and  DLZ.  During  the  procedure,  cal-
cium  channel  blockers  and  remifentanil  were  used  to  lower 
the  systolic  systemic  blood  pressure  down  to  80  mmHg. 
Rapid  right  ventricular  pacing  to  prevent  windsock  phenom-
enon,  which  is  recommended  by  several  programs,  was  not 
performed.  After  the  stent  graft  was  deployed,  aortography 
was  performed  to  ascertain  the  absence  of  endo-leak.  If  en-
do-leak was suspected, balloon dilatation of the stent graft or 
additional  stent  graft  implantation  was  performed.  Follow-up 
MDCT  was  done  at  one  week  after  the  procedure,  and  pa-
tients  were  follow-up  in  the  out-patient  department  at  post-
operative  1,  6  and  12  months.
RESULTS
    Endovascular  aneurismal  exclusion  was  confirmed  in  15 
patients  (15/16,  94%).  One  patient  showed  minimal  Type  1 
endoleak,  and  has  been  closely  followed  up  ever  since  the 
procedure  without  further  deterioration.  Cerebral  embolism 
occurred  in  four  patients:  Three  recovered  completely,  and 
one  developed  mild  right  side  motor  weakness.  Two  patients 
developed  left-sided  pleural  effusion,  which  was  drained  us-
ing  a  catheter  in  one.  There  was  no  surgical  mortality. 
D u r i n g  a  m e a n  f o l l o w - u p  d u r a t i o n  o f  1 8  m o n t h s  ( 1 ∼73 
months),  the  diameter  of  the  thoracic  aorta  covered  by  the 
stent  graft  changed  within  10%  range  in  12  patients,  de-
creased  by  more  than  10%  in  3,  and  increased  by  more  than 
10%  in  one  (Fig.  3).  There  was  no  late  death  related  to  the 
recurrence  of  the  original  aortic  disease.
DISCUSSION
    Stent  graft  TEVAR  for  various  thoracic  aortic  diseases  re-
portedly shows low morbidity and mortality compared to con-
ventional  surgical  approach  [1-4].  Technical  success  rate  of 
TEVAR (i.e. complete isolation of the anurtysmal cavity from 
the  aortic  circulation)  has  reached  up  to  98%,  while  early 
mortality  (1.9∼2.9%)  is  extremely  lower  than  that  (5.7∼
11.7%) of surgical series [2-4]. As for the morbidity, a recent 
report  claimed  that  TEVAR  resulted  in  lower  incidence Thoracic EndoVascular Stent Graft Repair for Aortic Aneurysm
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(9.4%)  of  morbidities,  including  myocardial  infarction,  respi-
ratory complications and cerebrospinal injury compared to the 
outcome  of  surgical  intervention  (33%)  [4].  Indications  for 
TAVAR  are  almost  the  same  as  those  for  surgical  inter-
vention,  that  are  dilated  aortic  diameter  equal  to  or  greater 
than 5.5 cm, increase in aortic size by greater than 1 cm per 
year  during  the  follow-up,  traumatic  aortic  rupture,  persistent 
chest  pain,  peripheral  perfusion  failure  from  type  B  aortic 
dissection, and penetrating arotic ulcer larger than 2 cm in di-
ameter  [2]. 
    Traumatic aortic rupture is caused by an acute deceleration 
injury on the insertion site of ligamentum arteriosum, and fre-
quently  associated  with  multiple  trauma,  which  may  render 
the surgical outcome even worse. In this setting, TEVAR is a 
formidable  alternative  to  a  surgical  intervention  by  minimiz-
ing the invasiveness of the repair [5]. Small sized stent grafts 
tend to be used for TEVAR for patients with traumatic aortic 
rupture  because  this  condition  frequently  occurs  in  younger 
population whose pre-trauma aortic size could well be normal. 
    With  respect  to  the  outcome  after  TEVAR  for  uncompli-
cated  type  B  dissection,  INSTEAD  (Investigation  of  stent 
graft  in  patients  with  type  B  aortic  dissection)  study  con-
ducted  in  Europe  showed  that  there  was  no  difference  in  1 
year  survival  between  TEVAR  group  and  medical  treatment 
group [6]. However, given that the size of the aorta increases 
as  time  passes,  the  longer  term  outcome  may  turn  out  to  be 
in  favor  of  TEVAR  strategy  [7].  To  the  contrary,  Iris  et  al 
observed that there was no difference in the size  of the false 
aortic  lumen  between  TEVAR  and  medical  treatment  groups, 
and  they  asserted  that  TEVAR  procedure  never  abolishes,  al-
beit  may  delay,  the  manifestation  of  the  adverse  outcome 
from  the  natural  progression  of  the  aortic  disease  [8].  In  our 
series,  there  was  one  patient  whose  aortic  diameter  increased 
as  time  passed. 
    As for chronic aortic dissection, partial thrombus formation 
in  the  false  lumen  is  believed  to  increase  the  risk  of  rupture 
and death [9]. Thus, the benefits from TEVAR in comparison 
to  surgical  approach  is  still  controversial,  because  stent  graft 
only  obliterates  the  opening  of  the  entry  site  while  leaving 
reentry site uncovered, which may end up with partial throm-
bus  formation,  progressive  aortic  dilation  and  rupture  of  the 
thoracic  aorta. 
    Surgical correction of acute type B dissection involving the 
origin  of  arch  vessels  is  associated  with  significant  morbidity 
and  high  mortality  rate  [10].  Arch  vessels  obstruction  is 
caused  by  intimal  flap  occluding  the  origins  of  the  vessels, 
and  obstruction  can  be  either  static  (i.e.  fixed  obstruction)  or 
dynamic  (i.e.  intermittent  obstruction  according  to  the cardiac 
cycle) [11]. Arch dissection with static obstruction of the arch 
vessels  necessitate  self-expandable  stent  insertion  into  the 
arch  vessels, and  communication between the  true  lumen and 
arch  vessel origins is established either by fenestration of the 
stent  graft  or  by  the  use  of  separate  bare  stent  at  the  arch 
level.  On  the  contrary,  arch  dissection  with  dynamic  ob-
struction  of  the  arch  vessels  only  requires  obliteration  of  the 
entry  site  by  stent  graft  so  that  intermittent  expansion  of  the 
initmal flap during the systolic phase is prevented [11]. Early 
and  late  mortality  after  surgery  for  patients  who  had  under-
gone TEVAR for arch dissection with arch vessel obstruction 
are reported to be 17% and 36%, respectively, which appears 
to be much better than the mortality after conventional surgi-
cal  repair  for  acute  arch  dissection  (40%)  [11].  This  finding 
signifies  that  the  application  of  TEVAR  to  arch  dissection  is 
designed to convert a complicated type B dissection involving 
arch vessels into an uncomplicated chronic type B dissection, 
which  is  much  more  amenable  to  a  surgical  intervention.  In 
this regards, Szeto et al asserted that TEVAR should be con-
sidered as the fist-line treatment for complicated type B acute 
dissection  (i.e.  rupture  or  arch  obstruction),  evidenced  by  the 
low procedure-related mortality (3%) in 35 patients with com-
plicated  arch  dissection  [12].  However,  some  argue  that  the 
risk  of  false  lumen  rupture  in  type-B  dissection  with  arch 
vessel  obstruction  remains  significant  even  after  TEVAR  is 
performed  [13].  As  for  uncomplicated  type  B  dissection, 
ADSORB  (Acute  Uncomplicated  Aortic  Dissection  Type  B: 
Evaluating  Stent-Graft  Placement  or  Best  Medical  Treatment 
Alone)  study  has  investigated  on  the  benefits  of  stent  graft 
over  medical  treatment,  which  has  not  reached  a  conclusion 
yet.  Timing  of  TEVAR  for  type  B  acute  dissection  is  also 
controversial.  Some  prefer  to  delay  the  procedure  to  2∼4 
weeks  after  the  onset,  based  on  the  findings  that  intimal  flap 
is  fragile  and  easily  breakable  during  early  period  [14,15], 
while  others  believe  that  early  intervention  may  promote  the 
complete  restoration  of  the  aortic  integrity,  and  thus  could Joung Taek Kim, et al
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improve  the  long-term  outcome  [16,17].  In  a  study  which 
compared  the  outcomes  after  TEVAR  and  medical  treatment 
for  acute  type  B  dissection  [10],  the  authors  insisted  that 
there  was  no  difference  in  the  development  of  complication 
or  mortality,  and  therefore  TEVAR  should  be  reserved  only 
for  complicated  type  B  dissection.  Akira  et  al  stratified  the 
patients according to the diameter of the aorta, and they con-
cluded  that  TEVAR  should  be  indicated  for  patients  whose 
maximal  aortic  diameter  is  greater  than  40  mm,  based  on 
their  observations  that  60%  of  the  patients  with  large  aorta 
(≥40  mm  in  diameter)  showed  enlargement  of  the  false  lu-
men  and  underwent  a  surgical  intervention  while  94%  of  the 
patients  with  small  aorta  (≤40  mm  in  diameter)  showed 
spontaneous  obliteration  of  the  false  lumen  [18]. 
    Preoperative  computed  tomographic  angiography  can  be 
utilized  for  the  evaluation  of  the  arch  vessels,  and,  if  basilar 
artery  mal-perfusion  after  TEVAR  is  anticipated  due  to  poor 
collateral circulation to the left subclavian artery or left domi-
nance  of  vertebral  artery  circulation,  graft  interposition  be-
tween  the  left  subcalvian  artery  and  left  common  carotid  ar-
tery  should  be  performed  beforehand.  If  the  stent  graft  is  to 
cover  the  left  common  carotid  artery  too,  graft  interposition 
between  both  common  carotid  arteries  should  also  be  per-
formed  before  TEVAR  procedure.  If  the  innominate  artery  is 
to  be  covered,  all  three  arch  vessels  should  be  debranched 
and  reimplanted  into  the  proximal  ascending  aorta  through 
median  sternotomy  [3].  Special  care  should  be  taken  to  pre-
vent  cerebrospinal  injury  upon  TEVAR  procedure.  Cerebral 
embolism of atheromatous plaques may take place during the 
catheter  work  or  graft  stenting,  and  left  vertebral  artery  mal-
perfusion may  lead to posterior cerebral infarction when  PLZ 
violates  the  origin  of  the  left  subclavian  artery.  Furthermore, 
spinal  cord  injury  is  likely  to  occur  when  more  than  15  cm 
of  the  descending  thoracic  aorta  is  covered  by  the  stent  graft 
or DLZ is less than 5 cm away from the origin of the celiac 
trunk  [2].
    As  to  the  complications  after  TEVAR,  post-implantation 
syndrome  refers  to  inflammatory  responses  after  TEVAR 
characterized by leukocytosis, mild fever and the elevation of 
the  inflammatory  markers,  and  is  attributed  to  the  activation 
of  the  intimal  cells  of  the  aorta.  Reactive  pleural  effusion 
may  also  occur  in  37∼73%  of  the  patients.  Distal  migration 
o f  t h e  s t e n t  g r a f t  m o r e  t h a n  1 0  m m  o f f  t h e  o r i g i n a l  s i t e  i s  
observed in 1∼2.8% of the patients, and too large stent graft 
or  variability  of  the  luminal  curvature  in  the  proximity  of 
PLZ  are  thought  to  be  the  risk  factors  for  stent  graft  migra-
tion  [2].
    Postoperative  evaluation  is  based  on  the  findings  of 
MDCT, which is to be performed at postoperative 1,6 and 12 
months, and annually from that on. If type 1 endo-leak is de-
tected  on  MDCT,  immediate  intervention  is  recommended, 
a n d ,  i f  t y p e  2  e n d o - l e a k  i s  s u spected,  close  follow-up  focus-
ing  on  the  size  change  of  the  aneurysm  is  suggested. 
    The  application  of  TEVAR  using  stent  graft  has  not  been 
fully established yet. Traumatic aortic rupture and descending 
thoracic  aneurysm  seem  to  be  best  benefitted  from  this  new 
therapeutic  modality,  and  TEVAR  is  expected  to  rapidly  re-
place  the  conventional  surgical  approach.  As  for  aortic  arch 
dissection  involving  arch  vessels,  employment  of  hybrid  pro-
cedure  (i.e.  TEVAR  with  surgical  interventions  for  arch  ves-
sels) will increase [3]. The efficacy of TEVAR for acute type 
B  dissection  is  still  under  debate:  Some  are  insisting  that 
TEVAR  does  not  change  the  natural  course  of  the  false  lu-
men  while  others  claim  that  TEVAR  may  contribute  to  the 
regression  of  the  false  lumen  by  thrombus  formation  and  ab-
sorption  [8,19].  Thus,  further  study  with  longer-term  fol-
low-up  is  necessary  to  delineate  the  benefits  from  TEVAR 
for  this  subset. 
CONCLUSION
Intermediate-term  outcome  after  TEVAR  was  encouraging. 
Indications  for  TEVAR  could  be  extended  for  other  thoracic 
aortic  diseases. 
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